254 related articles for article (PubMed ID: 21530132)
1. Isolation and characterization of process-related impurities and degradation products in larotaxel.
Che X; Shen L; Xu H; Liu K
J Pharm Biomed Anal; 2011 Jul; 55(5):1190-6. PubMed ID: 21530132
[TBL] [Abstract][Full Text] [Related]
2. Identification, isolation, characterization and response factor determination of process-related impurity in meprobamate drug substance.
Karthikeyan K; Arularasu GT; Murali V; Pillai KC
J Pharm Biomed Anal; 2011 Jan; 54(1):208-12. PubMed ID: 20727702
[TBL] [Abstract][Full Text] [Related]
3. Isolation and characterization of degradation impurities in docetaxel drug substance and its formulation.
Kumar D; Tomar RS; Deolia SK; Mitra M; Mukherjee R; Burman AC
J Pharm Biomed Anal; 2007 Mar; 43(4):1228-35. PubMed ID: 17126518
[TBL] [Abstract][Full Text] [Related]
4. Drug-excipient compatibility testing-Identification and characterization of degradation products of phenylephrine in several pharmaceutical formulations against the common cold.
Douša M; Gibala P; Havlíček J; Plaček L; Tkadlecová M; Břicháč J
J Pharm Biomed Anal; 2011 Jul; 55(5):949-56. PubMed ID: 21481557
[TBL] [Abstract][Full Text] [Related]
5. A validated stability-indicating RP-HPLC method for levofloxacin in the presence of degradation products, its process related impurities and identification of oxidative degradant.
Lalitha Devi M; Chandrasekhar KB
J Pharm Biomed Anal; 2009 Dec; 50(5):710-7. PubMed ID: 19632800
[TBL] [Abstract][Full Text] [Related]
6. Isolation and characterization of impurities in docetaxel.
Vasu Dev R; Moses Babu J; Vyas K; Sai Ram P; Ramachandra P; Sekhar NM; Mohan Reddy DN; Srinivasa Rao N
J Pharm Biomed Anal; 2006 Feb; 40(3):614-22. PubMed ID: 16330175
[TBL] [Abstract][Full Text] [Related]
7. Identification of pharmaceutical impurities in formulated dosage forms.
Pan C; Liu F; Motto M
J Pharm Sci; 2011 Apr; 100(4):1228-59. PubMed ID: 24081463
[TBL] [Abstract][Full Text] [Related]
8. Structural identification and characterization of potential degradants of zotarolimus on zotarolimus-coated drug-eluting stents.
Chen Q; Zielinski D; Chen J; Nowak S; Zhou CC
J Pharm Biomed Anal; 2009 Dec; 50(5):778-86. PubMed ID: 19581067
[TBL] [Abstract][Full Text] [Related]
9. LC and LC-MS study of stress decomposition behaviour of isoniazid and establishment of validated stability-indicating assay method.
Bhutani H; Singh S; Vir S; Bhutani KK; Kumar R; Chakraborti AK; Jindal KC
J Pharm Biomed Anal; 2007 Mar; 43(4):1213-20. PubMed ID: 17118610
[TBL] [Abstract][Full Text] [Related]
10. The use of LC/MS, GC/MS, and LC/NMR hyphenated techniques to identify a drug degradation product in pharmaceutical development.
Pan C; Liu F; Ji Q; Wang W; Drinkwater D; Vivilecchia R
J Pharm Biomed Anal; 2006 Feb; 40(3):581-90. PubMed ID: 16242883
[TBL] [Abstract][Full Text] [Related]
11. A critical review on the use of modern sophisticated hyphenated tools in the characterization of impurities and degradation products.
Singh S; Handa T; Narayanam M; Sahu A; Junwal M; Shah RP
J Pharm Biomed Anal; 2012 Oct; 69():148-73. PubMed ID: 22521633
[TBL] [Abstract][Full Text] [Related]
12. Development of Impurity Profiling Methods Using Modern Analytical Techniques.
Ramachandra B
Crit Rev Anal Chem; 2017 Jan; 47(1):24-36. PubMed ID: 27070830
[TBL] [Abstract][Full Text] [Related]
13. Detection, identification and quantification of a new de-fluorinated impurity in casopitant mesylate drug substance during late phase development: an analytical challenge involving a multidisciplinary approach.
Turco L; Provera S; Curcuruto O; Bernabè E; Nicoletti A; Martini L; Castoldi D; Cimarosti Z; Papini D; Marchioro C; Dams R
J Pharm Biomed Anal; 2011 Jan; 54(1):67-73. PubMed ID: 20813481
[TBL] [Abstract][Full Text] [Related]
14. HPLC separation, synthesis, isolation and characterization of process related and degradation impurities in larotaxel including method development and validation.
Yao K; Wang H; Xie X; Li J; You R; Li Y; Zhang H
J Pharm Biomed Anal; 2023 Sep; 233():115435. PubMed ID: 37196590
[TBL] [Abstract][Full Text] [Related]
15. A validated stability-indicating LC method for acetazolamide in the presence of degradation products and its process-related impurities.
Srinivasu P; Subbarao DV; Vegesna RV; Sudhakar Babu K
J Pharm Biomed Anal; 2010 May; 52(1):142-8. PubMed ID: 20053517
[TBL] [Abstract][Full Text] [Related]
16. Identification, isolation and characterization of process-related impurities in Rizatriptan benzoate.
Raj TJ; Bharathi Ch; Kumar MS; Prabahar J; Kumar PN; Sharma HK; Parikh K
J Pharm Biomed Anal; 2009 Jan; 49(1):156-62. PubMed ID: 19056198
[TBL] [Abstract][Full Text] [Related]
17. Identification and characterization of degradation products of dicloxacillin in bulk drug and pharmaceutical dosage forms.
Raj TJ; Bharati CH; Rao KR; Rao PS; Narayan GK; Parikh K
J Pharm Biomed Anal; 2007 Mar; 43(4):1470-5. PubMed ID: 17125952
[TBL] [Abstract][Full Text] [Related]
18. Isolation and characterization of process related impurities and degradation products of bicalutamide and development of RP-HPLC method for impurity profile study.
Nageswara Rao R; Narasa Raju A; Narsimha R
J Pharm Biomed Anal; 2008 Feb; 46(3):505-19. PubMed ID: 18162355
[TBL] [Abstract][Full Text] [Related]
19. Identification, isolation and characterization of potential degradation products in pioglitazone hydrochloride drug substance.
Ramulu K; Kumar TT; Krishna SR; Vasudev R; Kaviraj M; Rao BM; Rao NS
Pharmazie; 2010 Mar; 65(3):162-8. PubMed ID: 20383934
[TBL] [Abstract][Full Text] [Related]
20. Isolation and structure characterization of related impurities in etimicin sulfate by LC/ESI-MS(n) and NMR.
Wang H; Zhang Z; Xiong F; Wu L; Li P; Ye W
J Pharm Biomed Anal; 2011 Jul; 55(5):902-7. PubMed ID: 21444173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
